Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment

1. Morales-Barrera, R.
2. Villacampa, G.
3. Vidal, N.
4. Figols, M.
5. Giner, J.
6. Bonfill, T.
7. Suárez, C.
8. Díaz, N.
9. Mateo, J.
10. González, M.
11. Domenech, M.
12. Puente, J.
13. Carles, J.